药物警戒
不利影响
医学
不良事件报告系统
事件(粒子物理)
体重增加
重症监护医学
药物不良事件
药理学
内科学
梅德林
急诊医学
风险评估
安全概况
药物代谢
生物信息学
事件数据
作者
Leidan Zhang,Ling Chen,Jia Tang,Xiaosheng Liu,liyuan Zheng,Fada Wang,Xin Huang,Wei Cao,Taisheng Li
出处
期刊:Hiv Medicine
[Wiley]
日期:2026-03-03
卷期号:27 (5): 749-760
被引量:3
摘要
OBJECTIVE: Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged. This study aimed to evaluate the association between INSTIs and metabolic adverse events (AEs), including weight gain and glucose/lipid disorders. DESIGN: The US Food and Drug Administration Adverse Event Reporting System (FAERS) reports from the first quarter (Q1) of 2004 through Q1 2025 were analysed for AEs associated with bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL), focusing on weight gain and glucose/lipid metabolism disorders. Kaplan-Meier curves and Weibull shape parameter tests were used to analyse the cumulative incidence and time to onset of AEs. RESULTS: All four INSTIs were associated with safety signals for weight gain and glucose/lipid metabolism disorders. BIC had the highest reporting odds ratio (ROR) for weight gain (ROR: 7.70, 95% CI: 7.00-8.47), while DTG had the highest for glucose/lipid disorders (1.81, 95% CI: 1.66-1.97). Younger age and female sex were linked to BIC-related weight gain; older age was a risk factor for DTG-, EVG- and RAL-related glucose/lipid AEs. DTG-associated events occurred earlier than those with other agents. CONCLUSION: This study identified metabolic AEs associated with INSTIs, with agent-specific differences in risk and timing, highlighting the need for regular monitoring and individualized management during INSTI-based ART.
科研通智能强力驱动
Strongly Powered by AbleSci AI